CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation

Inclusion Criteria

• •Patients of any age who have previously undergone allogeneic hematopoietic transplantation and have evidence of donor cell engraftment (\>20% donor cell within three months of study entry)
• •Expected survival \>4 weeks
• •CML patients with molecular, cytogenetic or hematologic relapse following allogeneic transplantation
• •CML patients with accelerated phase or blast crisis following allogeneic transplantation
• •Patients with CLL, NHL, MM, or HD who have evidence of disease relapse or persistent disease at 60 days post-allo BMT and/or:
• •1. MM- patients with a rising M-protein is detectable at 180 days post-transplant
• •2. NHL - patients with molecular evidence of disease (bcl-2, t (4,11), etc.) at 180 days post transplant
• •3. CLL, NHL or HD - patients with clear cut evidence of tumor growth at any time post-transplant are eligible
• •Patients undergoing an HLA -identical or 5/6 antigen match transplant from a related or unrelated donor
• •Patient's original donor must be available for lymphocyte donation
• •There must be no evidence of active acute or graft-versus-host disease and patients should be off all immunosuppressive agents for, at least, two weeks prior to DLI. Patients on stable dose of methylprednisolone (\<16 mg/d) without evidence of active GVHD are also eligible.
• •Patients must have a Zubrod PS\<2 (see appendix 7), Cr\<2.5, bilirubin \<3, and transaminases (SGPT, SGOT) \<4x normal
• •Patient must be able to sign informed consent